157 related articles for article (PubMed ID: 6286773)
1. Specific binding of phospholipid platelet-activating factor by human platelets.
Valone FH; Coles E; Reinhold VR; Goetzl EJ
J Immunol; 1982 Oct; 129(4):1637-41. PubMed ID: 6286773
[TBL] [Abstract][Full Text] [Related]
2. Modulation of cytoplasmic calcium in human platelets by the phospholipid platelet-activating factor 1-O-alkyl-2-acetyl-SN-glycero-3-phosphorylcholine.
Valone FH; Johnson B
J Immunol; 1985 Feb; 134(2):1120-4. PubMed ID: 2578151
[TBL] [Abstract][Full Text] [Related]
3. Specific binding by human polymorphonuclear leucocytes of the immunological mediator 1-O-hexadecyl/octadecyl-2-acetyl-sn-glycero-3-phosphorylcholine.
Valone FH; Goetzl EJ
Immunology; 1983 Jan; 48(1):141-9. PubMed ID: 6848449
[TBL] [Abstract][Full Text] [Related]
4. High affinity specific binding sites for tritiated platelet-activating factor in canine platelet membranes: counterparts of platelet-activating factor receptors mediating platelet aggregation.
Tahraoui L; Floch A; Mondot S; Cavero I
Mol Pharmacol; 1988 Aug; 34(2):145-51. PubMed ID: 2842653
[TBL] [Abstract][Full Text] [Related]
5. Activation of human neutrophils with 1-O-hexadecyl/octadecyl-2-acetyl-sn-glycerol-3-phosphorylcholine (platelet activating factor).
Shaw JO; Pinckard RN; Ferrigni KS; McManus LM; Hanahan DJ
J Immunol; 1981 Sep; 127(3):1250-5. PubMed ID: 6267133
[TBL] [Abstract][Full Text] [Related]
6. Inhibition of binding of the platelet-activating factor AGEPC to platelets by the AGEPC analog rac-3-(N-n-octadecylcarbamoyloxy)-2-methoxypropyl 2-thiazolioethyl phosphate (CV-3988).
Valone FH
Biochem Biophys Res Commun; 1985 Jan; 126(1):502-8. PubMed ID: 3970703
[TBL] [Abstract][Full Text] [Related]
7. Isolation of a platelet membrane protein which binds the platelet-activating factor 1-0-hexadecyl-2-acetyl-SN-glycero-3-phosphorylcholine.
Valone FH
Immunology; 1984 May; 52(1):169-74. PubMed ID: 6325330
[TBL] [Abstract][Full Text] [Related]
8. Activation of rabbit platelet phospholipase and thromboxane synthesis by 1-O-hexadecyl/octadecyl-2-acetyl-sn-glyceryl-3-phosphorylcholine (platelet activating factor).
Shaw JO; Klusick SJ; Hanahan DJ
Biochim Biophys Acta; 1981 Jan; 663(1):222-9. PubMed ID: 7213765
[TBL] [Abstract][Full Text] [Related]
9. Binding and internalization of platelet-activating factor 1-O-alkyl-2-acetyl-sn-glycero-3-phosphocholine in washed rabbit platelets.
Homma H; Tokumura A; Hanahan DJ
J Biol Chem; 1987 Aug; 262(22):10582-7. PubMed ID: 3038889
[TBL] [Abstract][Full Text] [Related]
10. Intravascular pathobiology of acetyl glyceryl ether phosphorylcholine (AGEPC), a synthetic platelet-activating factor (PAF). I. Intravenous infusion in guinea pigs.
Demopoulos CA; Tsabikakis GE; Kapoulas VM
Immunol Lett; 1981 Aug; 3(3):133-5. PubMed ID: 7287060
[TBL] [Abstract][Full Text] [Related]
11. Synergistic platelet activation by aggregates of IgG and the phospholipid platelet-activating factor 1-O-alkyl-2-acetyl-SN-glycero-3-phosphorylcholine.
Valone FH
J Clin Immunol; 1986 Jan; 6(1):57-64. PubMed ID: 3082920
[TBL] [Abstract][Full Text] [Related]
12. Platelet-activating factor binding to human platelet membranes.
Valone FH; Ruis NM
Biotechnol Appl Biochem; 1986 Oct; 8(5):465-70. PubMed ID: 3021183
[TBL] [Abstract][Full Text] [Related]
13. Decay of the activating signal after platelet stimulation with 1-0-alkyl-2-acetyl-SN-glycero-3-phosphorylcholine: changes in calcium permeability.
Valone FH; Johnson B
Thromb Res; 1985 Nov; 40(3):385-92. PubMed ID: 4082115
[TBL] [Abstract][Full Text] [Related]
14. Metabolic behavior of acetyl glyceryl ether phosphorylcholine on interaction with rabbit platelets.
Pieroni G; Hanahan DJ
Arch Biochem Biophys; 1983 Jul; 224(2):485-93. PubMed ID: 6870274
[TBL] [Abstract][Full Text] [Related]
15. Pharmacological characterization of a receptor for platelet-activating factor on guinea pig peritoneal macrophages using [3H]apafant, a selective and competitive platelet-activating factor antagonist: evidence that the noncompetitive behavior of apafant in functional studies relates to slow kinetics of dissociation.
Ring PC; Seldon PM; Barnes PJ; Giembycz MA
Mol Pharmacol; 1993 Feb; 43(2):302-12. PubMed ID: 8381515
[TBL] [Abstract][Full Text] [Related]
16. Ontogeny of the responsiveness to intravenous platelet-activating factor.
Angle MJ; Pinckard RN; Showell HJ; McManus LM
Lab Invest; 1987 Sep; 57(3):321-8. PubMed ID: 3626521
[TBL] [Abstract][Full Text] [Related]
17. Alkyl-ether phosphoglycerides influence calcium fluxes into human endothelial cells.
Bussolino F; Aglietta M; Sanavio F; Stacchini A; Lauri D; Camussi G
J Immunol; 1985 Oct; 135(4):2748-53. PubMed ID: 2411812
[TBL] [Abstract][Full Text] [Related]
18. Pathobiology of the intravenous infusion of acetyl glyceryl ether phosphorylcholine (AGEPC), a synthetic platelet-activating factor (PAF), in the rabbit.
McManus LM; Hanahan DJ; Demopoulos CA; Pinckard RN
J Immunol; 1980 Jun; 124(6):2919-24. PubMed ID: 7373056
[No Abstract] [Full Text] [Related]
19. Characterization of 1-O-alkyl-2-acetyl-sn-glycero-3-phosphocholine (AGEPC)-induced protein phosphorylation in rabbit platelets: inhibitory effects of AGEPC analogs.
Sugatani J; Hanahan DJ
Arch Biochem Biophys; 1986 May; 246(2):855-64. PubMed ID: 3754710
[TBL] [Abstract][Full Text] [Related]
20. Demonstration of a specific C3a receptor on guinea pig platelets.
Fukuoka Y; Hugli TE
J Immunol; 1988 May; 140(10):3496-501. PubMed ID: 3283237
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
